Abstract
Chronic Pain syndromes and Major Depressive Disorder account for two of the most costly and prevalent illnesses worldwide and are frequently comorbid and treatment resistant. In this review, we examine the current role of ketamine, a potent NMDA (N-methl-D-aspartic acid) receptor blocker, in treating chronic pain and major depression. The role of the NMDA receptor and glutamatergic system are increasingly being studied in mood disorders, and are known components in pain processing, opioid induced analgesic tolerance, and hyperalgesia. We propose a hypothetic therapeutic role of ketamine involving the opioidergic pathway in these patients with treatment resistant chronic pain and major depressive disorder.
Keywords: Chronic pain, ketamine, major depressive disorder, neuropathic pain, nmda receptor antagonist, opioid tolerance, opioid resistance, analgesic, hyperalgesia, dysthymia, antidepressant, neurotransmitters, glutamate receptor, synaptic plasticity, coincidence detector, cholinergic receptors, kappa opioid receptors, psychomimetic, serotonin, anesthetic effect, cerebral vasodilation, hallucinations, nightmares, morphine, benzodiazepine, tachyarrhythmias, schizophrenia, allodynia, lidocaine, postherpetic neuralgia, xerostomia, Limb Pain, Fibromyalgia, Pluronic lecithin organogel, Stump/Phantom, Whiplash Pain, Placebo-controlled, Montgomery, –, Asberg Depression Rating Scale, lamotrigine, epidural, Opioidergic, Glutamatergic Dysfunction, naloxone
Current Drug Therapy
Title: Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis
Volume: 5 Issue: 4
Author(s): Christine Chang, David Bezov and Marco Pappagallo
Affiliation:
Keywords: Chronic pain, ketamine, major depressive disorder, neuropathic pain, nmda receptor antagonist, opioid tolerance, opioid resistance, analgesic, hyperalgesia, dysthymia, antidepressant, neurotransmitters, glutamate receptor, synaptic plasticity, coincidence detector, cholinergic receptors, kappa opioid receptors, psychomimetic, serotonin, anesthetic effect, cerebral vasodilation, hallucinations, nightmares, morphine, benzodiazepine, tachyarrhythmias, schizophrenia, allodynia, lidocaine, postherpetic neuralgia, xerostomia, Limb Pain, Fibromyalgia, Pluronic lecithin organogel, Stump/Phantom, Whiplash Pain, Placebo-controlled, Montgomery, –, Asberg Depression Rating Scale, lamotrigine, epidural, Opioidergic, Glutamatergic Dysfunction, naloxone
Abstract: Chronic Pain syndromes and Major Depressive Disorder account for two of the most costly and prevalent illnesses worldwide and are frequently comorbid and treatment resistant. In this review, we examine the current role of ketamine, a potent NMDA (N-methl-D-aspartic acid) receptor blocker, in treating chronic pain and major depression. The role of the NMDA receptor and glutamatergic system are increasingly being studied in mood disorders, and are known components in pain processing, opioid induced analgesic tolerance, and hyperalgesia. We propose a hypothetic therapeutic role of ketamine involving the opioidergic pathway in these patients with treatment resistant chronic pain and major depressive disorder.
Export Options
About this article
Cite this article as:
Chang Christine, Bezov David and Pappagallo Marco, Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis, Current Drug Therapy 2010; 5 (4) . https://dx.doi.org/10.2174/157488510792927447
DOI https://dx.doi.org/10.2174/157488510792927447 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances on Neural Tube Defects with Special Reference to Valproic Acid
Endocrine, Metabolic & Immune Disorders - Drug Targets Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology A Chemical Genetics Approach for Specific Differentiation of Stem Cells to Somatic Cells: A New Promising Therapeutical Approach
Combinatorial Chemistry & High Throughput Screening Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Neuroprotective Effects of Melanocortins in CNS Injury
Current Pharmaceutical Design The Role of T-Type Calcium Channels in Epilepsy and Pain
Current Pharmaceutical Design The Effects of IGF-1 on Trk Expressing DRG Neurons with HIV-gp120- Induced Neurotoxicity
Current HIV Research Magnetic Nanoparticles: Properties, Synthesis and Biomedical Applications
Current Drug Metabolism The Nuclear Molecular Imaging of Protein Brain Receptors in Chronic Pain
Current Protein & Peptide Science Neuroserpin in Bipolar Disorder
Current Topics in Medicinal Chemistry Drugs of Abuse-Induced Hyperthermia, Blood-Brain Barrier Dysfunction and Neurotoxicity: Neuroprotective Effects of a New Antioxidant Compound H-290/51
Current Pharmaceutical Design Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design Directed Differentiation and Paracrine Mechanisms of Mesenchymal Stem Cells: Potential Implications for Tendon Repair and Regeneration
Current Stem Cell Research & Therapy Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nanog Overexpression Increases Neural Marker Expression in Adipose Derived Stem Cells
Recent Patents on Regenerative Medicine